Search Result

Results for "

GlyT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GlyT (23) 5-HT Receptor (2) Deubiquitinase (1) Endogenous Metabolite (5) iGluR (1) Isotope-Labeled Compounds (2) P2X Receptor (2)
By Research Areas:	Cancer (2) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (17)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: GlyT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112432

GlyT1 Inhibitor 1

GlyT Neurological Disease

GlyT1 Inhibitor 1 is a potent and selective GlyT1 inhibitor with an IC₅₀ of 38 nM for rGlyT1 . Antipsychotic activity .
HY-111029A

ALX-1393 TFA

GlyT Others

ALX-1393 TFA, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

GlyT1 Inhibitor 1	GlyT	Neurological Disease
GlyT1 Inhibitor 1 is a potent and selective *GlyT1* inhibitor with an IC₅₀ of 38 nM for rGlyT1 . Antipsychotic activity .

ALX-1393 TFA	GlyT	Others
ALX-1393 TFA, a selective *GlyT2* inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-138935

Iclepertin BI-425809	GlyT	Neurological Disease
Iclepertin (BI-425809) is a potent, selective and orally active glycine transporter 1 (GlyT1) inhibitor. Iclepertin is inactive against GlyT2. Iclepertin can be used for Alzheimer disease and schizophrenia research .

HY-14568

DCCCyB	GlyT	Neurological Disease
DCCCyB is an orally bioavailable, potent, and selective inhibitor of *GlyT1. DCCCyB demonstrates excellent in vivo occupancy of GlyT*1 transporters in rhesus monkey .

HY-10712

Org-24598	GlyT	Neurological Disease
Org-24598 is an inhibitor of glycine transporter 1 GlyT-1 . Org-24598 can inhibit the specific binding of [ ³H] CHIBIA-3007 to the rat brain membranes with a Ki value of 16.9 nM .

HY-19887

Tilapertin

AMG747

Tilapertin is an oral inhibitor of glycine transporter type-1 (GlyT1).

Tilapertin AMG747
Tilapertin is an oral inhibitor of glycine transporter type-1 (GlyT1).

HY-10809

Bitopertin 1 Publications Verification RG1678; RO4917838	GlyT	Neurological Disease
Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human *GlyT1* with a concentration exhibiting IC50 of 25 nM.

HY-100416A

LY2365109 hydrochloride	GlyT	Neurological Disease
LY2365109 hydrochloride is a potent and selective *GlyT1* inhibitor, with an IC₅₀ of 15.8 nM for glycine uptake in cells over-expressing hGlyT1a .

HY-111029

ALX-1393

GlyT Neurological Disease

ALX-1393, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

ALX-1393	GlyT	Neurological Disease
ALX-1393, a selective *GlyT2* inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-113202S1

Stearoyl-L-carnitine-d9 chloride	Isotope-Labeled Compounds GlyT	Metabolic Disease
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .

HY-10809A

Bitopertin (R enantiomer) RG1678 (R enantiomer); RO4917838 (R enantiomer)	GlyT	Neurological Disease
Bitopertin R enantiomer (RG1678 R enantiomer; RO4917838 R enantiomer) is the R-enantiomer of Bitopertin. Bitopertin is a potent, noncompetitive glycine reuptake inhibitor, inhibits glycine uptake at human *GlyT1* with a concentration exhibiting IC50 of 25 nM.

HY-130466

Stearoyl-L-carnitine chloride 1 Publications Verification	Endogenous Metabolite GlyT	Metabolic Disease
Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of *GlyT2*. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM .

HY-10716A

PF-03463275	GlyT	Neurological Disease
PF-03463275 is a centrally penetrant, orally available, selective, and competitive *GlyT1* (glycine transporter-1) reversible inhibitor, with a K_i of 11.6 nM. PF-03463275 has the potential for Schizophrenia research .

HY-110176

ASP2535	GlyT	Neurological Disease
ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .

HY-107527

Org 25543 hydrochloride	GlyT	Neurological Disease
Org 25543 hydrochloride is a selective and irreversible *GlyT2* inhibitor (IC₅₀: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice .

HY-10715

SSR504734	GlyT	Neurological Disease
SSR504734 is an orally active, selective and reversible inhibitor of human, rat, and mouse *GlyT1* (IC₅₀=18, 15, and 38 nM, respectively). SSR504734 shows anti-schizophrenia, anti-anxiety and anti-depression activities .

HY-10711A

ALX-5407 hydrochloride (R)-NFPS hydrochloride
ALX-5407 ((R)-NFPS) hydrochloride is a selective and orally active glycine transporter *GlyT1* inhibitor with an IC₅₀ value of 3 nM. ALX-5407 hydrochloride can be used the research of N-methyl-D-aspartate-receptor function and schizophrenia .

HY-148708

Oleoyl-D-lysine	iGluR	Neurological Disease
Oleoyl-D-lysine is a selective Glycine Transporter-2 (GlyT2) inhibitor based on lipid. Oleoyl-D-lysine reverses neuropathic pain in mice, shows antidrowsiness effect on chronic neuropathic pain. Oleoyl-D-lysine is safe and effective without respiratory depression .

HY-130466S

Stearoyl-L-carnitine-d3 chloride	Endogenous Metabolite GlyT	Metabolic Disease
Stearoyl-L-carnitine-d₃ (chloride) is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM[1][2].

HY-101037

Sarcosine N-Methylglycine; Sarcosin
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .

HY-122666

Org 25935	GlyT	Metabolic Disease
Org 25935 is a potent and selective glycine transporter 1 protein (GlyT1) inhibitor with an IC₅₀ value of 100 nM. Org 25935 can decrease ethanol (EtOH) intake and EtOH preference in rats, whereas water intake is unaffected. Org 25935 can be used for researching alcohol dependence or abuse .

HY-107526

(Rac)-ALX 5407 (Rac)-NFPS	GlyT	Neurological Disease
NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC₅₀s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively . NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion .

HY-18638

TCID 1 Publications Verification 4,5,6,7-Tetrachloroindan-1,3-dione	Deubiquitinase	Neurological Disease
TCID (4,5,6,7-Tetrachloroindan-1,3-dione) is a potent and selective neuronal ubiquitin C-terminal hydrolase (UCH-L3) inhibitor with an IC₅₀ of 0.6 μM . TCID diminishes glycine transporter GlyT2 ubiquitination in brainstem and spinal cord primary neurons .

HY-101037S1

Sarcosine-d3 N-Methylglycine-d₃; Sarcosin-d₃	Isotope-Labeled Compounds Endogenous Metabolite GlyT	Cancer
Sarcosine-d₃ is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-103332

N-Arachidonylglycine NA-Gly	GlyT Endogenous Metabolite	Inflammation/Immunology
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits *GLYT2* (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

HY-101037S

Sarcosine-15N N-Methylglycine-¹⁵N; Sarcosin-¹⁵N	Endogenous Metabolite GlyT	Cancer
Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-109067

Opiranserin VVZ-149	GlyT 5-HT Receptor P2X Receptor	Neurological Disease
Opiranserin (VVZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC₅₀s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC₅₀=0.87 μM). Opiranserin is development as an injectable agent for the treatment of postoperative pain .

HY-109067A

Opiranserin hydrochloride VVZ-149 hydrochloride	GlyT 5-HT Receptor P2X Receptor	Neurological Disease
Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC₅₀s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC₅₀=0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-130466

Stearoyl-L-carnitine chloride 1 Publications Verification	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite GlyT
Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of *GlyT2*. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM .

HY-103332

N-Arachidonylglycine NA-Gly	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	GlyT Endogenous Metabolite
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits *GLYT2* (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .

Cat. No.	Product Name	Chemical Structure

HY-130466S

Stearoyl-L-carnitine-d3 chloride
Stearoyl-L-carnitine-d₃ (chloride) is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2. Stearoyl-L-carnitine chloride inhibits glycine responses by 16.8% at concentrations up 3 μM[1][2].

HY-101037S1

Sarcosine-d3
Sarcosine-d₃ is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-101037S

Sarcosine-15N
Sarcosine- ¹⁵N is the ¹⁵N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].

HY-113202S1

Stearoyl-L-carnitine-d9 chloride
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride is an endogenous long-chain acylcarnitine. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

GlyT

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products